

CERTIFICATE

Survey of 29 November 2019

You have fulfilled the requirements of the External Quality Assessment with the following analysis

Virus Genome Detection - Human Papilloma Viruses (373):

Validity 12 months:

Differentiation of "High Risk" and "Low Risk" types of HPV (R: B3)

Typing of "High Risk" HPV and "Low Risk" HPV (R: B3)

(R) analysis is subject to the RiliBÄK

Participant:

41385

Mrs. Sandra Wojtowicz
EUROIMMUN POLAND
Genetic Laboratory EUROIMMUN DNA
ul. Widna 2a
50-543 Wrocław

Düsseldorf, 20 December 2019



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)



Prof. Dr. rer. nat. Heinz Zeichhardt
(Adviser)

CERTIFICATE OF PARTICIPATION

Survey of 29 November 2019

You have participated in the External Quality Assessment with the following analysis

Virus Genome Detection - Human Papilloma Viruses (373):

Differentiation of "High Risk" and "Low Risk" types of HPV (R: B3)

Typing of "High Risk" HPV and "Low Risk" HPV (R: B3)


(R) analysis is subject to the RiliBÄK

Participant:

41385

Mrs. Sandra Wojtowicz
EUROIMMUN POLAND
Genetic Laboratory EUROIMMUN DNA
ul. Widna 2a
50-543 Wrocław

Düsseldorf, 20 December 2019



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)



Prof. Dr. rer. nat. Heinz Zeichhardt
(Adviser)